Journal of the American Society of Nephrology
2008 JASN IMPACT FACTOR 7.505 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


Published ahead of print on October 11, 2006
J Am Soc Nephrol 17: 3257-3262, 2006
© 2006 American Society of Nephrology
doi: 10.1681/ASN.2006050543
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ASN.2006050543v1
17/11/3257    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Opelz, G.
Right arrow Articles by Döhler, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Opelz, G.
Right arrow Articles by Döhler, B.

Clinical Transplantation

No Improvement of Patient or Graft Survival in Transplant Recipients Treated with Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Type 1 Receptor Blockers: A Collaborative Transplant Study Report

Gerhard Opelz*, Martin Zeier{dagger}, Gunter Laux*, Christian Morath{dagger} and Bernd Döhler*

Departments of * Transplantation Immunology and {dagger} Nephrology, University of Heidelberg, Heidelberg, Germany

Address correspondence to: Prof. Gerhard Opelz, Department of Transplantation Immunology, Institute of Immunology, University of Heidelberg, Im Neuenheimer Feld 305, D-69120 Heidelberg, Germany. Phone: +49-6221-56-4013; Fax: +49-6221-56-4200; gerhard.opelz{at}med.uni-heidelberg.de

Received for publication May 31, 2006. Accepted for publication August 27, 2006.

It was reported recently that treatment of kidney transplant recipients with angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II type 1 receptor blockers (ARB) is associated with strikingly improved long-term graft and patient survival. This finding has important implications for future posttransplantation therapy recommendations. In an analysis of 17,209 kidney and 1744 heart transplant recipients, an association of treatment with ACEI/ARB with improved transplant outcome could not be confirmed. It is concluded that recommendations for a widespread use of ACEI/ARB treatment in transplant recipients are unwarranted.




This article has been cited by other articles:


Home page
 CJASNHome page
A. C. Shirali and M. J. Bia
Management of Cardiovascular Disease in Renal Transplant Recipients
Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 491 - 504.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
A. M. Jevnikar and R. B. Mannon
Late Kidney Allograft Loss: What We Know about It, and What We Can Do about It
Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(Supplement_2): S56 - S67.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
G. Heinze and R. Oberbauer
Does size matter?
Nephrol. Dial. Transplant., September 1, 2007; 22(9): 2725 - 2726.
[Full Text] [PDF]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673